For how long should we use symptomatic therapies to treat people with Alzheimer disease?

Kenneth Rockwood

doi:10.1177/070674371405901201

For how long should we use symptomatic therapies to treat people with Alzheimer disease?

Kenneth Rockwood

Office of Academic Affairs

Research output: Contribution to journal › Editorial › peer-review

7 Citations (Scopus)

Original language	English
Pages (from-to)	615-617
Number of pages	3
Journal	Canadian Journal of Psychiatry
Volume	59
Issue number	12
DOIs	https://doi.org/10.1177/070674371405901201
Publication status	Published - Dec 1 2014

ASJC Scopus Subject Areas

Psychiatry and Mental health

Keywords

Alzheimer disease
Cholinesterase inhibitor
Clinical trial
Dementia
Donepezil
Galantamine
Rivastigmine
Symptoms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/070674371405901201

Cite this

@article{612b9c358c4a4b2e92ef3be0d8cf75c3,

title = "For how long should we use symptomatic therapies to treat people with Alzheimer disease?",

keywords = "Alzheimer disease, Cholinesterase inhibitor, Clinical trial, Dementia, Donepezil, Galantamine, Rivastigmine, Symptoms",

author = "Kenneth Rockwood",

year = "2014",

month = dec,

day = "1",

doi = "10.1177/070674371405901201",

language = "English",

volume = "59",

pages = "615--617",

journal = "Canadian Journal of Psychiatry",

issn = "0706-7437",